Composer · investment strategy
by Composer Technologies · via Composer
A daily, tactical biotech+tech strategy using leveraged ETFs. Above the long‑term trend it buys dips and fades rips; below it leans short or into bonds, guided by a short‑term “heat” score and volatility. Core tools: TQQQ, LABU, SQQQ, SPXU, BSV.
Description from Composer
of the return and risk figures:as the source publishes them
What $10,000 would have become, from the strategy's own published history, against the S&P 500 over the same dates. The basis is labelled.
This strategy doesn’t publish a performance history we can chart.
Each rule is quoted word for word from the strategy's own documents.
No rules extracted from this strategy’s text yet.
9 positions as of 2026-10-11
: the platform's backtest holdings, not a client account.
Compares the stated rules with the holdings (or, where none are published, a mix estimated from returns), using tests fixed before any results were seen.
0.1% of weight in (IVV: 3.0%)
1 fund (SEC N-PORT, as of 2026-05-31)
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100% · 2026-10-11 ()
12.3% of weight in (SPY: 0%)
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100% · 2026-10-11 ()
6 of 16 funds in its are : LABU, SPXL, SPXU, SQQQ, TQQQ, UVXY
This strategy’s rules haven’t been extracted yet, so there’s no claim to compare with. The measurement is still shown. : 100%
Strategies that share its Thematic label, from other sources first, strongest risk-adjusted return first.
Interactive Advisors
How much of what we look for this strategy has, and why anything is missing. Fields that don't apply to it aren't counted.
4 missing
The text the rules are quoted from, with where it came from.
Daily, it asks: is the market in an uptrend (SPY above its 200‑day average)? If yes, play offense: fade “too hot” moves with inverse funds (SQQQ/SPXU), buy biotech (LABU) on sharp selloffs, otherwise hold a tech‑heavy basket (TQQQ + big tech). If no, play defense: prefer inverse funds or short‑term bonds (BSV) when fear is high (UVXY), but still buy biotech on extreme washouts. RSI is a short‑term heat score (high=hot, low=washed‑out).
A daily, tactical biotech+tech strategy using leveraged ETFs. Above the long‑term trend it buys dips and fades rips; below it leans short or into bonds, guided by a short‑term “heat” score and volatility. Core tools: TQQQ, LABU, SQQQ, SPXU, BSV.
BIORECKED targets tech/biotech upside with risk controls. OOS annualized return ~49% vs SPY ~21% and Calmar ~1.13. Regime hedges help navigate downturns. Note: drawdowns can be larger (~44% vs ~19%), so for risk-tolerant investors seeking upside.
https://bit.ly/GenesisLaunch - https://bit.ly/investorcollabdiscord
Every value on file, each labelled with its calculation basis and as-of date.
| Backtest final value (from $10,000) | $181.9M | 2026-10-11 | |
| Backtest regulatory fees | $222k | 2026-10-11 | |
| Backtest slippage cost | $2.1M | 2026-10-11 |
| AI categories (Composer) | daily rebalance, inverse hedges, leveraged etfs, tactical, tech & biotech focus, trend + mean reversion, volatility-aware | 2026-10-11 | |
| Asset classes / instruments | equities | 2026-10-11 |
| Logic complexity (node count) | 77 | 2026-10-11 | |
| Rebalance frequency | daily | 2026-10-11 |
| Concentration (Herfindahl index, out-of-sample, as Composer reports it) | 0.24 | 2026-10-11 | |
| Ticker universe (assets the logic can hold) | show[ "AAPL", "AMD", "AMZN", "BSV", "LABU", "MSFT", "NVDA", "QQQ", "SPXL", "SPXU", "SPY", "SQQQ", "TQQQ", "TSLA", "TSM", "UVXY" ] | 2026-10-11 |
| Alpha vs SPY, out-of-sample (out-of-sample) | 0.12 | 2026-10-11 | |
| Beta vs SPY, out-of-sample (out-of-sample) | 1.78 | 2026-10-11 | |
| Correlation (R) vs SPY, out-of-sample (out-of-sample) | 0.64 | 2026-10-11 |
| Remixes (copies) | 37 | 2026-10-11 | |
| Watchers | 6 | 2026-10-11 |
| Community review status | ACTIVE | 2026-10-11 |
| Backtest length | 2,859 | 2026-10-11 | |
| Out-of-sample length | 883 | 2026-10-11 | |
| Return, backtest period (annualized) (backtest) | 137.32% | 2026-10-11 | |
| Return, backtest period (cumulative) (backtest) | 1819k% | 2026-10-11 | |
| Return, out-of-sample period (annualized) (out-of-sample) | 49.41% | 2026-10-11 | |
| Return, out-of-sample period (cumulative) (out-of-sample) | 308.97% | 2026-10-11 | |
| Return, trailing 1 day (out-of-sample) | 0.54% | 2026-10-11 | |
| Return, trailing 1 month (out-of-sample) | 7.79% | 2026-10-11 | |
| Return, trailing 1 week (out-of-sample) | 0.25% | 2026-10-11 | |
| Return, trailing 1 year (backtest) | 63.10% | 2026-10-11 | |
| Return, trailing 1 year (out-of-sample) | 63.09% | 2026-10-11 | |
| Return, trailing 2 weeks (out-of-sample) | 1.46% | 2026-10-11 | |
| Return, trailing 3 months (out-of-sample) | 11.50% | 2026-10-11 | |
| SPY annualized return over the backtest window (backtest) | 14.01% | 2026-10-11 |
| Calmar ratio, backtest period (backtest) | 3.00 | 2026-10-11 | |
| Calmar ratio, out-of-sample period (out-of-sample) | 1.13 | 2026-10-11 | |
| Maximum drawdown, backtest period (backtest) | -45.75% | 2026-10-11 | |
| Maximum drawdown, out-of-sample period (out-of-sample) | -43.82% | 2026-10-11 | |
| Sharpe ratio, backtest period (backtest) | 1.81 | 2026-10-11 | |
| Sharpe ratio, out-of-sample period (out-of-sample) | 1.19 | 2026-10-11 | |
| Sortino ratio, backtest period (backtest) | 3.06 | 2026-10-11 | |
| Sortino ratio, out-of-sample period (out-of-sample) | 1.78 | 2026-10-11 | |
| Standard deviation, backtest period (backtest) | 56.44% | 2026-10-11 | |
| Standard deviation, out-of-sample period (out-of-sample) | 40.95% | 2026-10-11 |
| Annualized turnover, backtest period (backtest) | 31.29 | 2026-10-11 | |
| Annualized turnover, out-of-sample period (out-of-sample) | 22.26 | 2026-10-11 | |
| Daily win rate, backtest period (backtest) | 57.05% | 2026-10-11 | |
| Daily win rate, out-of-sample period (out-of-sample) | 56.17% | 2026-10-11 |
Collective2
Composer Technologies · Composer
